Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5. Epub 2005 Sep 2. Erratum in: Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17882.

2.

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H.

PLoS Med. 2007 Mar;4(3):e90.

3.

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L.

Clin Cancer Res. 2011 Apr 15;17(8):2591-601. doi: 10.1158/1078-0432.CCR-10-1045. Epub 2011 Jan 19.

4.
5.

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.

Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.

6.

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M.

Breast Cancer Res Treat. 2006 Sep;99(1):97-101. Epub 2006 Mar 16.

PMID:
16541312
7.

Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.

Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ Jr, Broxmeyer HE, Kopelovich L, Nakshatri H.

Oncogene. 2007 May 17;26(23):3329-37. Epub 2006 Nov 27.

PMID:
17130833
8.

Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.

Baumbusch LO, Myhre S, Langerød A, Bergamaschi A, Geisler SB, Lønning PE, Deppert W, Dornreiter I, Børresen-Dale AL.

Mol Cancer. 2006 Oct 20;5:47.

9.

Prediction of breast cancer prognosis by gene expression profile of TP53 status.

Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C.

Cancer Sci. 2008 Feb;99(2):324-32. doi: 10.1111/j.1349-7006.2007.00691.x.

10.

Integrated gene expression profile predicts prognosis of breast cancer patients.

Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM.

Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16.

PMID:
18278552
11.

Population-based molecular prognosis of breast cancer by transcriptional profiling.

Ma Y, Qian Y, Wei L, Abraham J, Shi X, Castranova V, Harner EJ, Flynn DC, Guo L.

Clin Cancer Res. 2007 Apr 1;13(7):2014-22.

12.

Copper alters the conformation and transcriptional activity of the tumor suppressor protein p53 in human Hep G2 cells.

Tassabehji NM, VanLandingham JW, Levenson CW.

Exp Biol Med (Maywood). 2005 Nov;230(10):699-708.

PMID:
16246896
13.

High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.

Sawaki M, Ito Y, Akiyama F, Tokudome N, Horii R, Mizunuma N, Takahashi S, Horikoshi N, Imai T, Nakao A, Kasumi F, Sakamoto G, Hatake K.

Breast Cancer. 2006;13(2):172-8.

14.

p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y.

Clin Cancer Res. 2005 Oct 15;11(20):7328-33.

15.

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL.

Clin Cancer Res. 2006 Feb 15;12(4):1157-67.

16.

Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2.

Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK.

Cancer Res. 2008 Jun 15;68(12):4580-7. doi: 10.1158/0008-5472.CAN-08-0316.

17.

Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues.

Lumachi F, Marino F, Varotto S, Basso U.

Ann N Y Acad Sci. 2009 Sep;1175:89-92. doi: 10.1111/j.1749-6632.2009.04969.x.

PMID:
19796081
18.

Clinical significance of p53 and bcl-2 protein coexpression phenotypes in molecular breast cancer subtypes of pre-menopausal and post-menopausal African-American women.

Ihemelandu CU, Dewitty RL Jr, Leffall LD Jr, Suryanarayana SM, Frederick WA.

Am Surg. 2009 Sep;75(9):776-84; discussion 784.

PMID:
19774948
19.

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215. Epub 2009 Jan 5.

20.

Identification of a robust gene signature that predicts breast cancer outcome in independent data sets.

Korkola JE, Blaveri E, DeVries S, Moore DH 2nd, Hwang ES, Chen YY, Estep AL, Chew KL, Jensen RH, Waldman FM.

BMC Cancer. 2007 Apr 11;7:61.

Supplemental Content

Support Center